Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heart development protein with EGF-like domains 1 (HEG1)
- Target
- HEG1
- Molecular classification
- Other (Transmembrane protein with EGF-like domains), Cell junction protein
01
Overview
Heart development protein with EGF-like domains 1 (HEG1) is a conserved transmembrane protein containing EGF-like repeats, localized at endothelial cell-cell junctions[1][4]. It is essential for embryonic cardiovascular development, orchestrating endothelial cell junction formation and the maintenance of vascular integrity. HEG1 directly interacts with the Rasip1 and KRIT1 proteins, serving as a physical nexus for Rap1-dependent signaling that stabilizes cell junctions, negatively regulates RhoA/ROCK signaling, and controls vascular permeability[1][2]. Loss of HEG1 function results in defective heart and vessel structure in mice and zebrafish. HEG1 expression is also implicated in various cancers, particularly lung adenocarcinoma, where low expression correlates with worse prognosis, suggesting potential utility as a clinical biomarker[3].
- Other names
- Heart of glassProtein HEG homolog 1KIAA1237MST112MSTP112HEG
02
Biological functions
Negative regulation of Rho protein signal transductionNegative regulation of Rho-dependent protein serine/threonine kinase (ROCK) activityRegulation of membrane permeabilityVascular developmentEndothelial cell-cell junction assembly and stabilization
03
Disease associations
Cardiovascular disease (required for vascular integrity; mutations disrupt heart and vessel development[2])Cancer (serves as a prognostic biomarker in lung adenocarcinoma[3])
04
Safety considerations
Disruption leads to severe cardiovascular defects, loss of vascular integrity, and failure of vessel formation in animal models, indicating essential roles in development and homeostasis[2].
05
Biomarkers
HEG1 expression (prognostic marker for lung adenocarcinoma; lower expression is associated with poorer outcomes[3])
Beyond the preview
Go deeper on Heart development protein with EGF-like domains 1 (HEG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heart development protein with EGF-like domains 1 (HEG1).